Abstract: A process for producing a fluoroolefin of the formula: CF3CY═CXnHp wherein Y is a hydrogen atom or a halogen atom (i.e., fluorine, chlorine, bromine or iodine); X is a hydrogen atom or a halogen atom (i.e., fluorine, chlorine, bromine or iodine); n and p are integers independently equal to 0, 1 or 2, provided that (n+p)=2; comprising contacting, in the presence of a phase transfer catalyst, a compound of the formula: CF3C(R1aR2b) C(R3cR4d), wherein R1, R2, R3, and R4 are independently a hydrogen atom or a halogen selected from the group consisting of fluorine, chlorine, bromine and iodine, provided that at least one of R1, R2, R3, and R4 is halogen and there is at least one hydrogen and one halogen on adjacent carbon atoms; a and b are independently=0, 1 or 2 and (a+b)=2; and c and d are independently=0, 1, 2 or 3 and (c+d)=3; and at least one alkali metal hydroxide.

Abstract: Disclosed are methods of producing fluorinated alcohols which find particular use in the syntheses of pharmaceutical drugs. The methods comprise generally, the steps of (a) reacting a halogenated alkane with an alkyl vinyl ether to form an unsaturated halogenated aldehyde; (b) reducing the unsaturated halogenated aldehyde to form an unsaturated halogenated alcohol; and (c) reducing the unsaturated halogenated alcohol to form a fluorinated alcohol.

Abstract: Vinyl ether compounds having the formula: R—O—X—O—CH═CH2 wherein R is a radical having the formula: R1—CFH—CF2— or R1—CF═CF2—, wherein R1 is an unsubstituted or substituted aliphatic radical, an unsubstituted or substituted cyclic aliphatic radical, an unsubstituted or substituted aromatic radical, an unsubstituted or substituted araliphatic radical, or an unsubstituted or substituted heterocyclic radical, and X is an unsubstituted or substituted aliphatic radical, an un-substituted or substituted cyclic aliphatic radical, an unsubstituted or substituted aromatic radical, an unsubstituted or substituted araliphatic radical, or an unsubstituted or substituted heterocyclic radical. Curable compositions containing the vinyl ether compounds and methods in which substrate coating layers of the vinyl ether compositions are cured, particularly on optical devices, are also disclosed, as well as polymers polymerized from the vinyl ether compounds.

Abstract: Disclosed are methods of producing fluorinated alcohols which find particular use in the syntheses of pharmaceutical drugs. The methods comprise generally, the steps of (a) reacting a halogenated alkane with an alkyl vinyl ether to form an unsaturated halogenated aldehyde; (b) reducing the unsaturated halogenated aldehyde to form an unsaturated halogenated alcohol; and (c) reducing the unsaturated halogenated alcohol to form a fluorinated alcohol.

Abstract: Vinyl ether compounds having the formula:

Abstract: Vinyl ether compounds having the formula: R—O—X—O—CH═CH2 wherein R is a radical having the formula: R1—CFH—CF2— or R1—CF═CF—, wherein R1 is an unsubstituted or substituted aliphatic radical, unsubstituted or substituted cyclic aliphatic radical, an unsubstituted or substituted aromatic radical, an unsubstituted or substituted araliphatic radical, or an unsubstituted or substituted heterocyclic radical, and X is an unsubstituted or substituted aliphatic radical, an unsubstituted or substituted cyclic aliphatic radical, unsubstituted or substituted aromatic radical, unsubstituted or substituted araliphatic radical or an unsubstituted or substituted heterocyclic radical. Curable compositions containing the vinyl ether compounds and methods in which the substrate coating layers of the vinyl ether compositions are cured, particularly on optical devices, are also disclosed, as well as polymers polymerized from the vinyl ether compounds.

Abstract: Vinyl ether compounds having the formula: R—O—X—O—CH═CH2 wherein R is a radical selected from R1—CnHm—, R1—CnHm—C(═O)—, R1—CnHm—CH[—O—X—O—CH═CH2—], R1—CnHm—CH[—O—X—O—CH═CH2—]C(═O)—, R1—CnHm—CH[—C(═O)—O—X—O—CH═CH2—], R1—CnHm—CH[—C(═O)—O—X—0—CH═CH2—]C(═O)—, R1—[CFCl—CF2—]pCH2— and HCFCl—CF2—, wherein R1 is hydrogen, an unsubstituted or substituted fluorinated aliphatic radical, an unsubstituted or substituted fluorinated cyclic aliphatic radical, an unsubstituted or substituted fluorinated aromatic radical, an unsubstituted or substituted fluorinated araliphatic radical, or an unsubstituted or substituted fluorinated heterocyclic radi

Abstract: A compound having the formula: ##STR1## wherein: R is fluorine, hydrogen, an unsubstituted or substituted aliphatic or unsubstituted or substituted aromatic radical;R.sub.1 is an unsubstituted or substituted aliphatic radical, or unsubstituted or substituted aromatic radical; andR.sub.2 is hydrogen, an unsubstituted or substituted aliphatic radical, or unsubstituted or substituted aromatic radical.

Abstract: Heteroaryl-substituted deoxy glycerols represented by the general Formulas Ia, Ib and Ic: ##STR1## wherein: X is oxygen (--O--) or sulfur (--S--); R is substituted or unsubstituted straight or branched chain C.sub.1-30 alkyl or alkenyl, provided that a double bond of the alkenyl does not originate at the carbon atom bound to the X substituent; Het is a 5- to 9-membered heteroaryl mono- or bicyclic ring system having no more than 1 carbonyl carbon in the ring system, with 1 to 4 nitrogen atoms as the sole heteroatoms, one of which nitrogens is bonded to the glycero carbon; and Y is hydroxyl (--OH) or thiol (--SH), pharmaceutical compositions containing the same, and methods of using the compounds, are disclosed. The compounds exhibit antiviral and antibacterial activities.

Abstract: Aminoheterocycle-substituted glycerols of Formula I are disclosed: ##STR1## wherein one of A, B or C is --X--R, wherein X is --O-- or --S--, and R is a substituted or unsubstituted C.sub.12-24 alkyl or alkenyl, the substituent being one or more of halo, C.sub.1-3 alkoxy or cyano, provided that a double bond of the alkenyl does not originate at the carbon atom bound to X; and another of A, B or C is an aminoheterocycle ring substituent --Het--NH.sub.2, wherein Het is a 5 to 11-membered monocyclic, bicyclic or bicyclic fused heterocyclic ring moiety with at least 1 to 4 nitrogens atoms contained within the hetero cyclic moiety, one of which nitrogen atoms is bonded to the glycero carbon; and the remaining A, B, or C substituent is --OH. The compounds of Formula I, isomers, salts, pharmaceutical compositions and appliances incorporating the same, and methods of use thereof are also disclosed.

Abstract: Disclosed are the use of certain cycloalkyl- and aryl-phosphoethanolamines as anti-inflammatory, anti-arrhythmic and local anesthetic agents. These therapeutically active cycloalkyl- and aryl-phosphoethanolamines are of the general Formula I:R--O--PEA Iwherein R is an unsubstituted or a substituted C.sub.5-7 cycloalkyl or an unsubstituted or a substituted phenyl in which each substituent is hydrogen or an unsubstituted or substituted straight or branched C.sub.1-4 alkyl or C.sub.2-4 alkenyl, said substitution being one or more of C.sub.1-4 alkoxy, halo or cyano; and --O--PEA represents a phosphoethanolamine substituent. Also disclosed are intermediates for producing Formula I compounds.

Abstract: Novel retinoid phosphocholines are disclosed having the general Formula (I): ##STR1## wherein R represents a retinyl or retinoyl moiety. The optical and geometric isomers of compounds of Formula (I) and the pharmaceutically-acceptable salts thereof, are also disclosed. The subject compounds exhibit anti-tumor, anti-psoriatic and anti-inflammatory activities in addition to their inherent Vitamin A-like activities. The invention embraces the novel compounds, pharmaceutical compositions thereof, and methods of using the same.

Abstract: The present invention relates to novel, therapeutically active fatty alkyl and alkenyl ether glycerophosphoethanolamines bearing a heterocyclic ring substituent on the ethanolamine nitrogen, methods of using the compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing same. The novel, therapeutically active compounds and salts of the invention possess anti-tumor, anti-psoriatic, anti-inflammatory, and PAF antagonistic activities.

Abstract: Novel (o-acyl-p-N-acylamino-phenyl)-O-phosphoethanolamines and pharmaceutically acceptable salts thereof having anti-inflammatory activity, and pharmaceutical compositions containing same are disclosed. Certain novel intermediates are also disclosed.